ISTH DIC Subcommittee Communication on Anticoagulation In COVID-19
Although the current evidence is still insufficient, we provide a pragmatic approach to anticoagulation in COVID‐19, but stress the need for further trials in this area.
COVID-19 Associated Hypercoagulability Manifestations, Mechanisms, and Management
In this narrative review, we summarize clinical manifestations of COVID-19, mechanisms, monitoring considerations, and anticoagulant therapy. We also review unique considerations for COVID-19 patients who are on extracorporeal membrane oxygenation.
Extracorporeal Blood Purification Treatment Options For COVID-19: The Role of Immunoadsorption
Several extracorporeal blood purification therapies are now available, and most of them target endotoxins and/or the cytokines and aim improving the immune response. For this purpose, plasmapheresis and immunoadsorption may be an important adjunctive treatment option to manage the complications caused by cytokine storm in critically ill patients with COVID-19.
Thromboelastography Profiles of Critically Ill Patients With Coronavirus Disease 2019
A large proportion of critically ill patients with coronavirus disease 2019 have hypercoagulable thromboelastography profiles with additional derangements related to fibrinogen and platelet function. As the majority of patients have an elevated thromboelastography maximum amplitude, a follow-up study evaluating platelet aggregation would be instructive.
Cardiovascular Manifestations and Treatment Considerations In COVID-19
COVID-19 contributes to cardiovascular complications, including acute myocardial injury as a result of acute coronary syndrome, myocarditis, stress-cardiomyopathy, arrhythmias, cardiogenic shock, and cardiac arrest.
Early Respiratory Outcomes Following Cardiac Surgery in Patients With COVID-19
Although early respiratory outcomes of asymptomatic COVID‐19 patients who underwent early cardiac surgery appeared to be satisfactory, compared to the propensity‐scored matched non‐COVID group, the postoperative outcomes were worse, especially in the ICU readmitted patients. We suggest postponing cardiac operations unless the patient requires emergency surgery.
Role of Extracorporeal Membrane Oxygenation In COVID-19: A Systematic Review
Our study highlights the paucity of evidence and the need for further data to consolidate the efficacy of ECMO in improving patient outcomes.
Sulfated Polysaccharides Effectively Inhibit SARS-Cov-2 In Vitro
To this end, we suggest that treatment of fucoidans, nebulized heparin, or possibly TriS-heparin in combination with or without current antiviral therapies, should be assessed first in human primary epithelial cells and then in human patients suffering from COVID-19.
Approach to Acute Cardiovascular Complications in COVID-19 Infection
This review discusses the presentation and management of patients with severe cardiac complications of COVID-19 disease, with an emphasis on a Heart-Lung team approach in patient management.
Provision of ECPR during COVID-19: Evidence, Equity, and Ethical Dilemmas
The logistics of patient selection, expedient cannulation, healthcare worker safety, and post-resuscitation care must be weighed against the ethical considerations.
COVID-19: Myocardial Injury in Survivors
In summary, myocardial injury is common in hospitalized COVID-19 patients and not exclusive to those with ACS or PE. In this single-centre, single-timepoint convalescent study, myocardial injury was associated with cardiac abnormalities detected by CMR where troponin elevation is unexplained even when cardiac function is normal.
Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients
Herein, we briefly discuss some of the various approaches currently being investigated for the treatment of SARS-CoV-2 with a focus on potential benefits of TPE for selected critically ill patients.